Chinese Journal of Chromatography ›› 2026, Vol. 44 ›› Issue (9): 1038-1047.DOI: 10.3724/SP.J.1123.2025.03019
• Articles • Previous Articles Next Articles
CHEN Qian, MA Zhichao, LI Yaonan*(
)
Received:2025-03-24
Online:2026-09-08
Published:2026-09-17
Supported by:CLC Number:
CHEN Qian, MA Zhichao, LI Yaonan. Determination of two pancreatic stimulants in equine urine using ionic liquid-based deep eutectic solvent-assisted liquid-liquid microextraction and ultra-high performance liquid chromatography-tandem mass spectrometry[J]. Chinese Journal of Chromatography, 2026, 44(9): 1038-1047.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chrom-china.com/EN/10.3724/SP.J.1123.2025.03019
| Analyte | tR/min | Precursor (m/z) | Products (m/z) | CEs/V | RF lens/V |
|---|---|---|---|---|---|
| AH | 6.92 | 324.9 | 199.4*, 243.8 | 17.76, 23.98 | 53 |
| CP | 6.83 | 276.8 | 110.9*, 175.1 | 31.33, 17.59 | 41 |
Table 1 Retention times and MS data of AH and CP
| Analyte | tR/min | Precursor (m/z) | Products (m/z) | CEs/V | RF lens/V |
|---|---|---|---|---|---|
| AH | 6.92 | 324.9 | 199.4*, 243.8 | 17.76, 23.98 | 53 |
| CP | 6.83 | 276.8 | 110.9*, 175.1 | 31.33, 17.59 | 41 |
| DES | HBA | HBD | Molar ratio | State at room temperature |
|---|---|---|---|---|
| DES 1 | tetrabutylphosphonium hexafluorophosphate (B4PPF6) | PFP | 1∶2 | solid |
| DES 2 | tetrabutylphosphonium bis((trifluoromethyl)sulfonyl)imide (B4PNTF2) | PFP | 1∶2 | solid |
| DES 3 | N-butyl-pyridinium hexafluorophosphate (BpyPF6) | PFP | 1∶2 | solid |
| DES 4 | N-butyl-pyridinium bis((trifluoromethyl)sulfonyl)imide (BpyNTF2) | PFP | 1∶2 | liquid |
| DES 5 | tetrabutylammonium hexafluorophosphate (N4444PF6) | PFP | 1∶2 | solid |
| DES 6 | tetrabutylammonium bis((trifluoromethyl)sulfonyl)imide (N4444NTF2) | PFP | 1∶2 | solid |
| DES 7 | N-butyl-N-methylpyrrolidinium hexafluorophosphate (PP14PF6) | PFP | 1∶2 | liquid |
| DES 8 | N-butyl-N-methylpyrrolidinium bis((trifluoromethyl)sulfonyl)imide (PP14NTF2) | PFP | 1∶2 | liquid |
| DES 9 | N-butyl-N-methylpiperidinium hexafluorophosphate (P14PF6) | PFP | 1∶2 | liquid |
| DES 10 | N-butyl-N-methylpiperidinium bis((trifluoromethyl)sulfonyl)imide (P14NTF2) | PFP | 1∶2 | liquid |
| DES 11 | 1-butyl-3-methylimidazolium hexafluorophosphate (BMIMPF6) | PFP | 1∶2 | liquid |
| DES 12 | 1-butyl-3-methylimidazolium bis((trifluoromethyl)sulfonyl)imide (BMIMNTF2) | PFP | 1∶2 | liquid |
| DES 13 | N-butyl-N-methylmorpholinium hexafluorophosphate (EMMPPF6) | PFP | 1∶2 | solid |
| DES 14 | N-butyl-N-methylmorpholinium bis((trifluoromethyl)sulfonyl)imide (EMMPNTF2) | PFP | 1∶2 | liquid |
Table 2 Components, molar ratios and states at room temperature of 14 ionic liquid-based deep eutectic solvents (IL-DES)
| DES | HBA | HBD | Molar ratio | State at room temperature |
|---|---|---|---|---|
| DES 1 | tetrabutylphosphonium hexafluorophosphate (B4PPF6) | PFP | 1∶2 | solid |
| DES 2 | tetrabutylphosphonium bis((trifluoromethyl)sulfonyl)imide (B4PNTF2) | PFP | 1∶2 | solid |
| DES 3 | N-butyl-pyridinium hexafluorophosphate (BpyPF6) | PFP | 1∶2 | solid |
| DES 4 | N-butyl-pyridinium bis((trifluoromethyl)sulfonyl)imide (BpyNTF2) | PFP | 1∶2 | liquid |
| DES 5 | tetrabutylammonium hexafluorophosphate (N4444PF6) | PFP | 1∶2 | solid |
| DES 6 | tetrabutylammonium bis((trifluoromethyl)sulfonyl)imide (N4444NTF2) | PFP | 1∶2 | solid |
| DES 7 | N-butyl-N-methylpyrrolidinium hexafluorophosphate (PP14PF6) | PFP | 1∶2 | liquid |
| DES 8 | N-butyl-N-methylpyrrolidinium bis((trifluoromethyl)sulfonyl)imide (PP14NTF2) | PFP | 1∶2 | liquid |
| DES 9 | N-butyl-N-methylpiperidinium hexafluorophosphate (P14PF6) | PFP | 1∶2 | liquid |
| DES 10 | N-butyl-N-methylpiperidinium bis((trifluoromethyl)sulfonyl)imide (P14NTF2) | PFP | 1∶2 | liquid |
| DES 11 | 1-butyl-3-methylimidazolium hexafluorophosphate (BMIMPF6) | PFP | 1∶2 | liquid |
| DES 12 | 1-butyl-3-methylimidazolium bis((trifluoromethyl)sulfonyl)imide (BMIMNTF2) | PFP | 1∶2 | liquid |
| DES 13 | N-butyl-N-methylmorpholinium hexafluorophosphate (EMMPPF6) | PFP | 1∶2 | solid |
| DES 14 | N-butyl-N-methylmorpholinium bis((trifluoromethyl)sulfonyl)imide (EMMPNTF2) | PFP | 1∶2 | liquid |
Fig. 3 Effect of (a) molar ratio of HBA to HBD, (b) IL-DES volume, (c) pH, (d) concentration of NaCl, (e) vortex time and (f) centrifugal time on the extraction recoveries of AH and CP from equine urine (n=3)
| Analyte | Linear range/(ng/mL) | Regression equation | Point numbera | LOD/(ng/mL) | LOQ/(ng/mL) | r2 |
|---|---|---|---|---|---|---|
| AH | 0.2-20000 | y=37.1x+994.9 | 16 | 0.1 | 0.2 | 0.9999 |
| CP | 0.5-20000 | y=1005.7x+43854.5 | 15 | 0.2 | 0.5 | 0.9995 |
Table 3 Linear ranges, regression equations, LODs and LOQs of AH and CP (n=3)
| Analyte | Linear range/(ng/mL) | Regression equation | Point numbera | LOD/(ng/mL) | LOQ/(ng/mL) | r2 |
|---|---|---|---|---|---|---|
| AH | 0.2-20000 | y=37.1x+994.9 | 16 | 0.1 | 0.2 | 0.9999 |
| CP | 0.5-20000 | y=1005.7x+43854.5 | 15 | 0.2 | 0.5 | 0.9995 |
| Analyte | Added/(ng/mL) | Intra-day (n=5) | Inter-day (n=3) | ||
|---|---|---|---|---|---|
| Recovery/% | RSD/% | Recovery/% | RSD/% | ||
| AH | 0.2 | 96.1 | 1.6 | 93.0 | 5.5 |
| 0.5 | 97.2 | 3.1 | 97.1 | 0.7 | |
| 1 | 97.6 | 4.6 | 99.0 | 6.6 | |
| 10 | 95.7 | 4.9 | 98.5 | 2.7 | |
| 100 | 97.4 | 2.9 | 97.7 | 3.3 | |
| 1000 | 97.0 | 1.2 | 96.8 | 1.8 | |
| 10000 | 107.4 | 3.7 | 106.4 | 2.1 | |
| 20000 | 108.4 | 5.2 | 103.7 | 2.6 | |
| CP | 0.5 | 97.1 | 4.9 | 103.4 | 1.2 |
| 1 | 101.1 | 5.8 | 105.1 | 3.5 | |
| 10 | 104.3 | 2.4 | 105.1 | 3.2 | |
| 100 | 90.4 | 0.8 | 90.2 | 1.0 | |
| 1000 | 105.4 | 1.9 | 106.1 | 2.4 | |
| 10000 | 110.4 | 1.6 | 109.7 | 2.1 | |
| 20000 | 90.6 | 0.6 | 104.8 | 1.4 | |
Table 4 Recoveries, intra-day and inter-day RSDs of AH and CP at different levels from equine urine
| Analyte | Added/(ng/mL) | Intra-day (n=5) | Inter-day (n=3) | ||
|---|---|---|---|---|---|
| Recovery/% | RSD/% | Recovery/% | RSD/% | ||
| AH | 0.2 | 96.1 | 1.6 | 93.0 | 5.5 |
| 0.5 | 97.2 | 3.1 | 97.1 | 0.7 | |
| 1 | 97.6 | 4.6 | 99.0 | 6.6 | |
| 10 | 95.7 | 4.9 | 98.5 | 2.7 | |
| 100 | 97.4 | 2.9 | 97.7 | 3.3 | |
| 1000 | 97.0 | 1.2 | 96.8 | 1.8 | |
| 10000 | 107.4 | 3.7 | 106.4 | 2.1 | |
| 20000 | 108.4 | 5.2 | 103.7 | 2.6 | |
| CP | 0.5 | 97.1 | 4.9 | 103.4 | 1.2 |
| 1 | 101.1 | 5.8 | 105.1 | 3.5 | |
| 10 | 104.3 | 2.4 | 105.1 | 3.2 | |
| 100 | 90.4 | 0.8 | 90.2 | 1.0 | |
| 1000 | 105.4 | 1.9 | 106.1 | 2.4 | |
| 10000 | 110.4 | 1.6 | 109.7 | 2.1 | |
| 20000 | 90.6 | 0.6 | 104.8 | 1.4 | |
| Analyte | Sample | Extraction method | Extraction solvent | Extraction time/min | Detection technique | Linear range/(ng/mL) | Recovery/% | RSD/% | LOD/(ng/mL) | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|
| CP | human plasma | LPE | N-hexane (5 mL) | — | GC | 20000-100000 | 104-114 | 2.5-5.3 | — | [ |
AH CP | human urine | SPE | methylene chloride (15 mL) | — | MEKC | — | — | — | 50 | [ |
| AH | human plasma and urine | LPE | N-hexane (5 mL) | — | GC | 5000-40000 | plasma: 81-115 urine: 30-35 | plasma: 3.0-11.5 urine: 8.0-16.0 | — | [ |
| CP | human plasma | LLE | chloroform (5 mL) | 12 | GC | — | 94-100 | — | — | [ |
| CP | human plasma | LLE | ethyl acetate (6 mL) | >6 | GC-MS | 4000-44000 | — | — | — | [ |
| CP | human serum | LLE | toluene (1 mL) | >17 | HPLC | 2.5-300 | 78 | <2.7 | 0.5 | [ |
| CP | human serum | SPE | ENVI-18 cartridge | >2 | LC-ESI-MS | 25-400 | 96.5 | 8.2 | 2-3 | [ |
| CP | horse plasma | LLE | dichloromethane (16 mL) | 35 | HPLC | 0-300000 | >95 | 1.2-3.6 | 3.5 | [ |
AH CP | equine urine | IL-DES-VALLME | DES 14 (0.1 mL) | 6 | UHPLC-MS/MS | 0.2-20000 0.5-20000 | 93.0-108.4 90.4-110.4 | 0.7-6.6 0.8-5.8 | 0.1 0.2 | this work |
Table 5 Comparison of the proposed method with other methods for the determination of AH and CP in body fluids
| Analyte | Sample | Extraction method | Extraction solvent | Extraction time/min | Detection technique | Linear range/(ng/mL) | Recovery/% | RSD/% | LOD/(ng/mL) | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|
| CP | human plasma | LPE | N-hexane (5 mL) | — | GC | 20000-100000 | 104-114 | 2.5-5.3 | — | [ |
AH CP | human urine | SPE | methylene chloride (15 mL) | — | MEKC | — | — | — | 50 | [ |
| AH | human plasma and urine | LPE | N-hexane (5 mL) | — | GC | 5000-40000 | plasma: 81-115 urine: 30-35 | plasma: 3.0-11.5 urine: 8.0-16.0 | — | [ |
| CP | human plasma | LLE | chloroform (5 mL) | 12 | GC | — | 94-100 | — | — | [ |
| CP | human plasma | LLE | ethyl acetate (6 mL) | >6 | GC-MS | 4000-44000 | — | — | — | [ |
| CP | human serum | LLE | toluene (1 mL) | >17 | HPLC | 2.5-300 | 78 | <2.7 | 0.5 | [ |
| CP | human serum | SPE | ENVI-18 cartridge | >2 | LC-ESI-MS | 25-400 | 96.5 | 8.2 | 2-3 | [ |
| CP | horse plasma | LLE | dichloromethane (16 mL) | 35 | HPLC | 0-300000 | >95 | 1.2-3.6 | 3.5 | [ |
AH CP | equine urine | IL-DES-VALLME | DES 14 (0.1 mL) | 6 | UHPLC-MS/MS | 0.2-20000 0.5-20000 | 93.0-108.4 90.4-110.4 | 0.7-6.6 0.8-5.8 | 0.1 0.2 | this work |
|
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||